These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30600830)

  • 1. Recommendation for the management of dyslipidemia in Poland - Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy.
    Szymański FM; Barylski M; Cybulska B; Wożakowska-Kapłon B; Krasiński Z; Mamcarz A; Widecka K; Płatek AE; Dudek D; Mickiewicz A; Kobayashi A; Dzida G; Grajek S; Wełnicki M; Zubilewicz T; Ufnal M; Hering D; Mizia-Stec K; Kasprzak J; Koziński M; Imiela J; Narkiewicz K; Gorczyca I; Postuła M; Jaguszewski MJ; Filipiak KJ
    Cardiol J; 2018; 25(6):655-665. PubMed ID: 30600830
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot.
    Szymański FM; Mickiewicz A; Dzida G; Gorczyca-Głowacka I; Kozłowski D; Widecka K; Krasiński Z; Kobayashi A; Hering D; Mizia-Stec K; Kasprzak JD; Zubilewicz T; Narkiewicz K; Koziński M; Płatek AE; Ryś-Czaporowska A; Chełstowska B; Grajek S; Wełnicki M; Mamcarz A; Barylski M; Wożakowska-Kapłon B; Jaguszewski MJ; Gruchała M; Filipiak KJ
    Cardiol J; 2022; 29(1):1-26. PubMed ID: 34811718
    [No Abstract]   [Full Text] [Related]  

  • 3. [Actual problems of dyslipidaemia treatment in Poland - 2nd Declaration of Sopot. Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy].
    Wożakowska-Kapłon B; Filipiak KJ; Mamcarz A; Barylski M; Cybulska B; Dąbrowski R; Drożdż J; Dudek D; Dzida G; Franek E; Górny J; Grajek S; Haberka M; Imiela J; Jankowski P; Kasprzak JD; Koziński M; Kozłowski D; Mizia-Stec K; Narkiewicz K; Siebert J; Sinkiewicz W; Tykarski A; Widecka K; Zdrojewski T
    Kardiol Pol; 2014; 72(9):847-53. PubMed ID: 25231425
    [No Abstract]   [Full Text] [Related]  

  • 4. Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines.
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR; ;
    Rev Esp Cardiol (Engl Ed); 2014 Nov; 67(11):913-9. PubMed ID: 25443815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fondaparinux in the treatment of acute coronary syndromes in Poland--from theory to practice. Experts' group position paper endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy].
    Filipiak KJ; Wożakowska-Kapłon B; Witkowski A; Gierlotka M; Opolski G; Mamcarz A
    Kardiol Pol; 2015; 73(10):943-8. PubMed ID: 26521893
    [No Abstract]   [Full Text] [Related]  

  • 6. Simplifying the approach to the management of dyslipidemia.
    Gaziano JM; Gaziano TA
    JAMA; 2009 Nov; 302(19):2148-9. PubMed ID: 19920241
    [No Abstract]   [Full Text] [Related]  

  • 7. [Spanish interdisciplinary committee for cardiovascular disease prevention and the spanish society of cardiology position statement on dyslipidemia management. Differences between the European and american guidelines].
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR;
    Semergen; 2015 Apr; 41(3):149-57. PubMed ID: 25450438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-pill combinations (SPCs) and treatment of arterial hypertension in Poland. Expert consensus statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy.
    Tykarski A; Widecka K; Narkiewicz K; Wożakowska-Kapłon B; Gaciong Z; Grajek S; Grodzicki T; Januszewicz A; Wolf J; Prejbisz A; Kostka-Jeziorny K; Filipiak KJ
    Kardiol Pol; 2017; 75(12):1357-1367. PubMed ID: 29251761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.
    Genest J; McPherson R; Frohlich J; Anderson T; Campbell N; Carpentier A; Couture P; Dufour R; Fodor G; Francis GA; Grover S; Gupta M; Hegele RA; Lau DC; Leiter L; Lewis GF; Lonn E; Mancini GB; Ng D; Pearson GJ; Sniderman A; Stone JA; Ur E
    Can J Cardiol; 2009 Oct; 25(10):567-79. PubMed ID: 19812802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients - A consensus document.
    Ray S; Sawhney JPS; Das MK; Deb J; Jain P; Natarajan S; Sinha KK
    Indian Heart J; 2018; 70(5):736-744. PubMed ID: 30392515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Type 2 diabetes prevention. Experts' Group position paper endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy].
    Walicka M; Chomiuk T; Filipiak KJ; Mamcarz A; Olszanecka-Glinianowicz M; Wożakowska-Kapłon B; Wyleżoł M; Franek E
    Kardiol Pol; 2015; 73(10):949-57. PubMed ID: 26521842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines].
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR;
    Clin Investig Arterioscler; 2015; 27(1):36-44. PubMed ID: 25444651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond.
    Waite LH; Phan YL; Spinler SA
    J Am Pharm Assoc (2003); 2016; 56(3):284-92. PubMed ID: 27156942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New worldwide lipid guidelines.
    Saraf S; Ray KK
    Curr Opin Cardiol; 2015 Jul; 30(4):447-53. PubMed ID: 26049395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.
    MacNair K; Bugden S;
    Can J Cardiol; 2007 May; 23(6):481-2; author reply 483. PubMed ID: 17549843
    [No Abstract]   [Full Text] [Related]  

  • 16. [Loop diuretics: old and new ones--which one to choose in clinical practice? Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy and Working Group on Heart Failure].
    Mamcarz A; Filipiak KJ; Drożdż J; Nessler J; Tykarski A; Niemczyk M; Wożakowska-Kapłon B
    Kardiol Pol; 2015; 73(3):225-32. PubMed ID: 25791979
    [No Abstract]   [Full Text] [Related]  

  • 17. Problems with modified Framingham Risk Score.
    Stern RH
    Can J Cardiol; 2014 Feb; 30(2):248.e3. PubMed ID: 23830292
    [No Abstract]   [Full Text] [Related]  

  • 18. Polish Forum for Prevention Guidelines on Dyslipidaemia: update 2016.
    Cybulska B; Szostak WB; Filipiak KJ; Kopeć G; Drygas W; Kłosiewicz-Latoszek L; Knap K; Pająk A; Podolec J; Zdrojewski T; Czarnecka D; Jankowski P; Małecki M; Nowicka G; Stańczyk J; Sarnecka A; Członkowska A; Niewada M; Undas A; Windak A; Hoffman P; Podolec P
    Kardiol Pol; 2017; 75(2):187-190. PubMed ID: 28205202
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to letter from Stern--problem with modifying Framingham Risk Score.
    Grover S; Grégoire J; Anderson TJ
    Can J Cardiol; 2014 Feb; 30(2):248.e5. PubMed ID: 24095223
    [No Abstract]   [Full Text] [Related]  

  • 20. Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society.
    Saraf S; Ray KK
    Curr Opin Lipidol; 2014 Dec; 25(6):413-7. PubMed ID: 25268983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.